@article{article, title  = {{1.5-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study}},

 url = {{}},

 year = {{2014}},

 month = {{10}},

 author = {{Kuczyk M and Parker C and Vogelzang N and Sartor O and Bottomley D and Coleman R and Skjorestad I and Whaba M and Nilsson S}},

 volume = {{37}},

 journal = {{ONCOLOGY RESEARCH AND TREATMENT}},

 pages = {{178-178}},

 note = {{Accessed on 2025/10/10}}}